24-h blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas

1987 ◽  
Vol 24 (3) ◽  
pp. 181-192 ◽  
Author(s):  
Sotos Raptis ◽  
Asimina Mitrakou ◽  
Dimitrios Hadjidakis ◽  
Emmanuel Diamantopoulos ◽  
Costas Anastasiou ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Endocrine Pancreas ◽  
Oral Treatment ◽  
Type I ◽  
Type Ii ◽  
Artificial Endocrine Pancreas ◽  
Type Ii Diabetics

Does the Measurement of Serum Fructosamine Accurately Reflect Levels of Glycated Albumin in Insulin-Dependent Diabetes?

1987 ◽  
Vol 24 (1) ◽  
pp. 47-52 ◽  
Author(s):  
P H Winocour ◽  
D Bhatnagar ◽  
P Reed ◽  
H Dhar
Keyword(s):  
Blood Glucose ◽  
Glycated Albumin ◽  
Glycated Haemoglobin ◽  
Type I ◽  
Random Blood Glucose ◽  
Glucose Levels ◽  
Serum Fructosamine ◽  
Type Ii Diabetics ◽  
Group A ◽  
Insulin Dependent

We have measured serum glycated albumin (GSA) by affinity chromatography and immunoturbidimetry, and serum fructosamine using a Cobas FARA analyser in blood samples from 37 type I diabetics and 21 healthy controls. Random blood glucose and glycated haemoglobin levels were also measured. Glycated haemoglobin (HbA1) correlated with glycated albumin and fructosamine in the diabetic group. A less clear relationship was found between glycated albumin and fructosamine. HbA1, GSA and fructosamine correlated poorly with random blood glucose levels. These data indicate that serum fructosamine levels do not accurately reflect those of glycated albumin, as has recently been suggested, in type I insulin-dependent diabetics where glycaemic control fluctuates more than in type II diabetics. It is postulated that the two methods reflect varying glycaemic levels to a different degree, thereby accounting for the disparity.

scholarly journals Blood glucose control by an artificial endocrine pancreas in a patient with phaeochromocytoma

1985 ◽  
Vol 32 (5) ◽  
pp. 538-542
Author(s):  
Masayasu Hamaji ◽  
Masahiko Miyata ◽  
Ryuzo Kawamori ◽  
Motoaki Shichiri ◽  
Takashi Mashimo ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glucose Control ◽  
Endocrine Pancreas ◽  
Blood Glucose Control ◽  
Artificial Endocrine Pancreas

scholarly journals Significant Differences in the Prevalence of Elevated HbA1c Levels for Type I and Type II Diabetics Attending the Parirenyatwa Diabetic Clinic in Harare, Zimbabwe

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Kurai Z. Chako ◽  
Heather Phillipo ◽  
Erisi Mafuratidze ◽  
Danai Tavonga Zhou
Keyword(s):  
Public Health ◽  
Glycemic Control ◽  
Public Health Facility ◽  
Poor Glycemic Control ◽  
Type I ◽  
Type Ii ◽  
Cross Sectional ◽  
Significant Difference ◽  
Type Ii Diabetics ◽  
Hba1c Levels

Diabetics have chronically elevated glucose levels. High levels of glucose result in nonenzymatic formation of glycosylated haemoglobin (HbA1c). Therefore, elevated HbA1c is a good indicator of poorly controlled diabetes. We used the standard HbA1c method to determine glycemic control in diabetics attending a public health facility in Harare, Zimbabwe. Our study sought to assess the prevalence of elevated HbA1c amongst treated diabetics and compare the HbA1c levels by type of diabetes. The cross-sectional study was carried out at one of the main public health centres in Zimbabwe: the Parirenyatwa Group of Hospitals in Harare. Type I and type II diabetics were recruited and had their blood HbA1c levels measured. The standard one tailed proportion z test was used to test the hypothesis at 5% significance level. Combined prevalence of type I and type II diabetics with elevated HbA1c was 27%. There was no significant difference in levels of HbA1c by age and sex. Over half (54%) of Type I diabetics had elevated HbA1c, suggesting poor glycemic control. In contrast only 24% of the Type II diabetics studied had elevated HbA1c. The difference in proportion of Type I and Type II diabetics with elevated HbA1c suggestive of poor glycemic control was significant (P=0.0067).

Should the same glucose values be targeted for type I as for type II diabetics in pregnancy?

1997 ◽  
Vol 176 (1) ◽  
pp. S177
Author(s):  
DA Sacks ◽  
JS Greenspoon ◽  
G Wolde-Tsadik ◽  
W. Chen
Keyword(s):  
Type I ◽  
Type Ii ◽  
Type Ii Diabetics ◽  
In Pregnancy

EFFECTIVE MAINTENANCE OF BLOOD GLUCOSE BY USING ARTIFICIAL ENDOCRINE PANCREAS MODEL STG-22

ASAIO Journal ◽  
2002 ◽  
Vol 48 (2) ◽  
pp. 196
Author(s):  
Tetsuya Kono ◽  
Satoshi Ashizawa ◽  
Kazuhiro Hanaraki ◽  
Daniel J Oestmann ◽  
Yukihiko Nose ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Endocrine Pancreas ◽  
Artificial Endocrine Pancreas

No difference in hla gene frequencies among black type i diabetics, type ii diabetics and non-diabetics in nigeria

1984 ◽  
Vol 20 (6) ◽  
pp. 1489
Author(s):  
M.J. MacDonald ◽  
O.O. Famuyiwa ◽  
M. Marrari ◽  
R.J. Duquesnoy
Keyword(s):  
Type I ◽  
Type Ii ◽  
Gene Frequencies ◽  
Type Ii Diabetics

Serum and erythrocyte magnesium levels in type I and type II diabetics

1985 ◽  
Vol 22 (3) ◽  
pp. 185-190 ◽  
Author(s):  
Wim F. Vanroelen ◽  
Luc F. Gaal ◽  
Patricia E. Rooy ◽  
Ivo H. Leeuw
Keyword(s):  
Type I ◽  
Type Ii ◽  
Type Ii Diabetics

scholarly journals Retinal Inflammation, Oxidative Stress, and Vascular Impairment Is Ablated in Diabetic Mice Receiving XMD8-92 Treatment

2021 ◽  
Vol 12 ◽  
Author(s):  
Scott J. Howell ◽  
Chieh A. Lee ◽  
Julia C. Batoki ◽  
Thomas E. Zapadka ◽  
Sarah I. Lindstrom ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Diabetic Retinopathy ◽  
New Drugs ◽  
Type I ◽  
Type Ii ◽  
Diabetic Mice ◽  
Junction Protein ◽  
Type Ii Diabetics ◽  
Retinal Inflammation

The global number of diabetics continues to rise annually. As diabetes progresses, almost all of Type I and more than half of Type II diabetics develop diabetic retinopathy. Diabetic retinopathy is a microvascular disease of the retina, and is the leading cause of blindness in the working-age population worldwide. With such a significant health impact, new drugs are required to halt the blinding threat posed by this visual disorder. The cause of diabetic retinopathy is multifactorial, and an optimal therapeutic would halt inflammation, cease photoreceptor cell dysfunction, and ablate vascular impairment. XMD8-92 is a small molecule inhibitor that blocks inflammatory activity downstream of ERK5 (extracellular signal-related kinase 5) and BRD4 (bromodomain 4). ERK5 elicits inflammation, is increased in Type II diabetics, and plays a pathologic role in diabetic nephropathy, while BRD4 induces retinal inflammation and plays a role in retinal degeneration. Further, we provide evidence that suggests both pERK5 and BRD4 expression are increased in the retinas of our STZ (streptozotocin)-induced diabetic mice. Taken together, we hypothesized that XMD8-92 would be a good therapeutic candidate for diabetic retinopathy, and tested XMD8-92 in a murine model of diabetic retinopathy. In the current study, we developed an in vivo treatment regimen by administering one 100 μL subcutaneous injection of saline containing 20 μM of XMD8-92 weekly, to STZ-induced diabetic mice. XMD8-92 treatments significantly decreased diabetes-mediated retinal inflammation, VEGF production, and oxidative stress. Further, XMD8-92 halted the degradation of ZO-1 (zonula occludens-1), which is a tight junction protein associated with vascular permeability in the retina. Finally, XMD8-92 treatment ablated diabetes-mediated vascular leakage and capillary degeneration, which are the clinical hallmarks of non-proliferative diabetic retinopathy. Taken together, this study provides strong evidence that XMD8-92 could be a potentially novel therapeutic for diabetic retinopathy.

Sign in / Sign up

Export Citation Format

Share Document